Skip to content
Main Navigation
About us
Company profile
Our values
Our strategy
Board of Directors
Senior management
Our history
Research and development
Technology platform
Therapeutic areas
Pipeline
Scientific papers and presentations
Partnering
Our approach
Our partnerships
Investors
Share information
Events & Presentations
Financial reports & Presentations
Financial calendar
Shareholder meetings
Shareholder information
Analyst coverage
Corporate governance
ESG
Newsroom
Press Releases
Image library
Glossary
Careers
Search
Research and development
Scientific papers and presentations
Sharing our discoveries and developments in our tireless pursuit of breakthrough therapies
Newest first
Oldest first
Posters & Papers
Presentations
Search
Reset
19/11/2025
VB10.NEO: A Clinically-Validated Individualized Vaccine Platform
17/11/2025
PEGS 2025: Antigen Presenting Cell-Targeted Vaccines Show Durable Antigen-Specific Immune Tolerance in Mouse Models of Autoimmune Disease
07/11/2025
SITC 2025: Integrative analyses of multiomics data and biomarker readout demonstrate clinical and immunological relevance of individualized vaccine design via the NeoSELECT platform
21/08/2025
IUIS 2025: Antigen presenting cell-targeted vaccines show durable antigen-specific immune tolerance in mouse models of autoimmune disease
25/06/2025
NeoAG Summit 2025: Induction of Neoantigen-Specific Immune Responses by VB10.NEO in Combination with Atezolizumab in Heavily Pretreated Patients with Advanced Solid Tumors; Final Analysis of the Phase 1b VB N-02 Trial
Pages:
1
2
3
4
5
6
7
8
9
10
11
12
Load more
Sorry, nothing found in this query
Privacy statement
Cookie policy
Disclaimer
